Complex Post-traumatic Stress Disorder: What Symptomatological Specificities

NCT ID: NCT05070962

Last Updated: 2021-10-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-17

Study Completion Date

2023-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A better understanding of the Complex Post-Traumatic Stress Disorder would allow a management as close as possible to the specificities of this one, but also a better training of professionals and adapted therapeutic indications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Post-Traumatic Stress Disorder manifests itself in a multitude of symptoms and self-regulation difficulties in various domains (somatization and biological balance, attention and consciousness, regulation of affects and impulses, interpersonal relationships and relational capacities, perception of the aggressor and of the aggression, self-perception and identity, sense and belief system) as well as profound changes in personality and various comorbidities .In addition, dissociation, the origin and the resulting disorders also have some similarities to Complex Post-Traumatic Stress Disorder. Indeed, dissociation is thought to have a traumatic origin and the symptomatology (eg hyperesthesia, dissociative amnesia, anesthesia) is included in Complex Post-Traumatic Stress Disorder. We can then ask ourselves the following questions: is Complex Post-Traumatic Stress Disorder a dissociative disorder in its own right causing difficulties with self-regulation? What is the share of dissociation in Complex Post-Traumatic Stress Disorder?

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psychiatric Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clinical population

having experienced repeated and prolonged traumatic exposure

clinical population

Intervention Type OTHER

or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.

General population

Student volunteers from the University of Lille

clinical population

Intervention Type OTHER

or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

clinical population

or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

general poupulation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For clinical population;

* Age between 18 and 65 years old;
* Having experienced repeated and prolonged traumatic exposure;
* Able to understand and answer self-questionnaires;
* Having expressed their free and informed consent
* Affiliated with a social security scheme

For general population:

* Student volunteers from the University of Lille;
* Aged between 18 and 65 years old;
* Able to understand and answer self-questionnaires;
* Having expressed their free and informed consent.

Exclusion Criteria

For clinical population;

* People with difficulties in answering the self-questionnaires (e.g. incomprehension of items, emotional difficulties);
* Persons under tutorship or curatorship;
* Persons deprived of their liberty.

For general population:

* People with difficulties in answering the self-questionnaires (e.g. incomprehension of items, emotional difficulties);
* Persons under tutorship or curatorship;
* Persons deprived of their liberty;
* Persons having a link of subordination with the investigative team.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Raincy Montfermeil Hospital Group

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marion SIMION

Role: PRINCIPAL_INVESTIGATOR

USAP CHI Robert Ballanger

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

USAP CHI Robert Ballanger Boulevard Robert Ballanger

Aulnay-sous-Bois, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marion SIMION

Role: CONTACT

+ 33 6 76 25 00 26

Stéphane RUSINEK, Pr

Role: CONTACT

+33 3 20 41 67 87

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marion SIMION

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GHT_ CHIRB -RIPH2_003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.